TCM Biotech International Corp. (TPE:4169)

Market Cap	9.27B +206.6%
Revenue (ttm)	703.09M +4.9%
Net Income	-13.80M
EPS	-0.24
Shares Out	59.05M
PE Ratio	n/a
Forward PE	174.44
Dividend	0.36 (0.23%)
Ex-Dividend Date	n/a

Volume	130,782
Open	154.50
Previous Close	154.50
Day's Range	154.00 - 157.50
52-Week Range	53.60 - 250.00
Beta	0.14
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 12, 2026

About TCM Biotech International

TCM Biotech International Corp., a biotech company, engages in the research and development of drugs for liver diseases. The company offers medical devices, such as therapy for osteoarthritis, intra-articular implant of hyaluronic acid, automated blood cell separator, absorbable adhesion barrier material, prosthetic and orthotic accessory, and pellefeel mask pressure relief pad; and pharmaceuticals, including iron supplement, therapeutic agent for urinary system, expectorant/mucolytic agent, anticancer drug, antihypertensive drug, and antidiabe...

• Industry: Pharmaceutical Preparations
• Founded: 1998
• Country: Taiwan
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 4169

Financial Performance

In 2025, TCM Biotech International's revenue was 685.49 million, an increase of 2.84% compared to the previous year's 666.53 million. Earnings were 19.17 million, a decrease of -8.76%.